S176: DARATUMUMAB CARFILZOMIB LENALIDOMIDE AND DEXAMETHASONE AS INDUCTION THERAPY IN HIGH-RISK TRANSPLANT ELIGIBLE NEWLY DIAGNOSED MYELOMA PATIENTS: RESULTS OF THE PHASE 2 STUDY IFM 2018-04
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-06-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000843596.14661.b3 |
| _version_ | 1797287877608996864 |
|---|---|
| author | C. Touzeau A. Perrrot C. Hulin S. Manier M. Macro M.-L. Chretien L. Karlin O. Decaux C. Jacquet M. Tiab X. Leleu L. Planchce H. Avet-Loiseau P. Moreau |
| author_facet | C. Touzeau A. Perrrot C. Hulin S. Manier M. Macro M.-L. Chretien L. Karlin O. Decaux C. Jacquet M. Tiab X. Leleu L. Planchce H. Avet-Loiseau P. Moreau |
| author_sort | C. Touzeau |
| collection | DOAJ |
| first_indexed | 2024-03-07T18:41:10Z |
| format | Article |
| id | doaj.art-11989a769f9745f2bd28fcdf0aa6608c |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T18:41:10Z |
| publishDate | 2022-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-11989a769f9745f2bd28fcdf0aa6608c2024-03-02T03:51:39ZengWileyHemaSphere2572-92412022-06-016777810.1097/01.HS9.0000843596.14661.b3202206003-00077S176: DARATUMUMAB CARFILZOMIB LENALIDOMIDE AND DEXAMETHASONE AS INDUCTION THERAPY IN HIGH-RISK TRANSPLANT ELIGIBLE NEWLY DIAGNOSED MYELOMA PATIENTS: RESULTS OF THE PHASE 2 STUDY IFM 2018-04C. Touzeau0A. Perrrot1C. Hulin2S. Manier3M. Macro4M.-L. Chretien5L. Karlin6O. Decaux7C. Jacquet8M. Tiab9X. Leleu10L. Planchce11H. Avet-Loiseau12P. Moreau131 CHU Nantes - Hotel Dieu, CHU Nantes - Hotel Dieu, Nantes2 Hematology, IUCT Oncopole, Toulouse3 Hematology, CHU Bordeaux, Bordeaux4 Hematology, CHU Lille, Lille5 Hematology, CHU Caen, Caen6 Hematology, CHU Dijon, DIjon7 Hematology, CHU Lyon, Lyon8 Hematology, CHu Rennes, Rennes9 Hematology, CHU Nancy, Nancy10 Hematology, CHD, La Roche sur Yon11 Hematology, CHU Poitiers, Poitiers12 Biostatistic2 Hematology, IUCT Oncopole, Toulouse13 Hematology, CHU Nantes, Nantes, Francehttp://journals.lww.com/10.1097/01.HS9.0000843596.14661.b3 |
| spellingShingle | C. Touzeau A. Perrrot C. Hulin S. Manier M. Macro M.-L. Chretien L. Karlin O. Decaux C. Jacquet M. Tiab X. Leleu L. Planchce H. Avet-Loiseau P. Moreau S176: DARATUMUMAB CARFILZOMIB LENALIDOMIDE AND DEXAMETHASONE AS INDUCTION THERAPY IN HIGH-RISK TRANSPLANT ELIGIBLE NEWLY DIAGNOSED MYELOMA PATIENTS: RESULTS OF THE PHASE 2 STUDY IFM 2018-04 HemaSphere |
| title | S176: DARATUMUMAB CARFILZOMIB LENALIDOMIDE AND DEXAMETHASONE AS INDUCTION THERAPY IN HIGH-RISK TRANSPLANT ELIGIBLE NEWLY DIAGNOSED MYELOMA PATIENTS: RESULTS OF THE PHASE 2 STUDY IFM 2018-04 |
| title_full | S176: DARATUMUMAB CARFILZOMIB LENALIDOMIDE AND DEXAMETHASONE AS INDUCTION THERAPY IN HIGH-RISK TRANSPLANT ELIGIBLE NEWLY DIAGNOSED MYELOMA PATIENTS: RESULTS OF THE PHASE 2 STUDY IFM 2018-04 |
| title_fullStr | S176: DARATUMUMAB CARFILZOMIB LENALIDOMIDE AND DEXAMETHASONE AS INDUCTION THERAPY IN HIGH-RISK TRANSPLANT ELIGIBLE NEWLY DIAGNOSED MYELOMA PATIENTS: RESULTS OF THE PHASE 2 STUDY IFM 2018-04 |
| title_full_unstemmed | S176: DARATUMUMAB CARFILZOMIB LENALIDOMIDE AND DEXAMETHASONE AS INDUCTION THERAPY IN HIGH-RISK TRANSPLANT ELIGIBLE NEWLY DIAGNOSED MYELOMA PATIENTS: RESULTS OF THE PHASE 2 STUDY IFM 2018-04 |
| title_short | S176: DARATUMUMAB CARFILZOMIB LENALIDOMIDE AND DEXAMETHASONE AS INDUCTION THERAPY IN HIGH-RISK TRANSPLANT ELIGIBLE NEWLY DIAGNOSED MYELOMA PATIENTS: RESULTS OF THE PHASE 2 STUDY IFM 2018-04 |
| title_sort | s176 daratumumab carfilzomib lenalidomide and dexamethasone as induction therapy in high risk transplant eligible newly diagnosed myeloma patients results of the phase 2 study ifm 2018 04 |
| url | http://journals.lww.com/10.1097/01.HS9.0000843596.14661.b3 |
| work_keys_str_mv | AT ctouzeau s176daratumumabcarfilzomiblenalidomideanddexamethasoneasinductiontherapyinhighrisktransplanteligiblenewlydiagnosedmyelomapatientsresultsofthephase2studyifm201804 AT aperrrot s176daratumumabcarfilzomiblenalidomideanddexamethasoneasinductiontherapyinhighrisktransplanteligiblenewlydiagnosedmyelomapatientsresultsofthephase2studyifm201804 AT chulin s176daratumumabcarfilzomiblenalidomideanddexamethasoneasinductiontherapyinhighrisktransplanteligiblenewlydiagnosedmyelomapatientsresultsofthephase2studyifm201804 AT smanier s176daratumumabcarfilzomiblenalidomideanddexamethasoneasinductiontherapyinhighrisktransplanteligiblenewlydiagnosedmyelomapatientsresultsofthephase2studyifm201804 AT mmacro s176daratumumabcarfilzomiblenalidomideanddexamethasoneasinductiontherapyinhighrisktransplanteligiblenewlydiagnosedmyelomapatientsresultsofthephase2studyifm201804 AT mlchretien s176daratumumabcarfilzomiblenalidomideanddexamethasoneasinductiontherapyinhighrisktransplanteligiblenewlydiagnosedmyelomapatientsresultsofthephase2studyifm201804 AT lkarlin s176daratumumabcarfilzomiblenalidomideanddexamethasoneasinductiontherapyinhighrisktransplanteligiblenewlydiagnosedmyelomapatientsresultsofthephase2studyifm201804 AT odecaux s176daratumumabcarfilzomiblenalidomideanddexamethasoneasinductiontherapyinhighrisktransplanteligiblenewlydiagnosedmyelomapatientsresultsofthephase2studyifm201804 AT cjacquet s176daratumumabcarfilzomiblenalidomideanddexamethasoneasinductiontherapyinhighrisktransplanteligiblenewlydiagnosedmyelomapatientsresultsofthephase2studyifm201804 AT mtiab s176daratumumabcarfilzomiblenalidomideanddexamethasoneasinductiontherapyinhighrisktransplanteligiblenewlydiagnosedmyelomapatientsresultsofthephase2studyifm201804 AT xleleu s176daratumumabcarfilzomiblenalidomideanddexamethasoneasinductiontherapyinhighrisktransplanteligiblenewlydiagnosedmyelomapatientsresultsofthephase2studyifm201804 AT lplanchce s176daratumumabcarfilzomiblenalidomideanddexamethasoneasinductiontherapyinhighrisktransplanteligiblenewlydiagnosedmyelomapatientsresultsofthephase2studyifm201804 AT havetloiseau s176daratumumabcarfilzomiblenalidomideanddexamethasoneasinductiontherapyinhighrisktransplanteligiblenewlydiagnosedmyelomapatientsresultsofthephase2studyifm201804 AT pmoreau s176daratumumabcarfilzomiblenalidomideanddexamethasoneasinductiontherapyinhighrisktransplanteligiblenewlydiagnosedmyelomapatientsresultsofthephase2studyifm201804 |